PharmaNutra SpA (MIL:PHN) ROCE % : 20.16% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is PharmaNutra SpA ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PharmaNutra SpA's annualized ROCE % for the quarter that ended in Mar. 2024 was 20.16%.

PharmaNutra SpA ROCE % Historical Data

The historical data trend for PharmaNutra SpA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaNutra SpA ROCE % Chart

PharmaNutra SpA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

40.05

36.44

39.57

36.41

30.24

PharmaNutra SpA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															33.50	36.25	23.56	28.18	20.16

PharmaNutra SpA ROCE % Calculation

PharmaNutra SpA's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	24.062	/	( ( (100.155 - 25.79)	+	(112.443 - 27.648) )	/ 2 )
	=	24.062	/	( (74.365	+	84.795)	/ 2 )
	=	24.062	/	79.58
	=	30.24 %

PharmaNutra SpA's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	17.244	/	( ( (112.443 - 27.648)	+	(115.375 - 29.069) )	/ 2 )
	=	17.244	/	( ( 84.795	+	86.306 )	/ 2 )
	=	17.244	/	85.5505
	=	20.16 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

PharmaNutra SpA (MIL:PHN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

PharmaNutra SpA ROCE % Related Terms

Thank you for viewing the detailed overview of PharmaNutra SpA's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmaNutra SpA (MIL:PHN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PharmaNutra SpA (MIL:PHN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

761:Germany

Address

Via Delle Lenze, 216/b, Pisa, ITA, 56122

Website

https://www.pharmanutra.it

PharmaNutra SpA is a pharmaceutical company. It is engaged in the research, design, development, and marketing of nutraceutical supplements and medical devices. Its products include SiderAL Folic, UltraMag, Cetilar, Gestalys DHA, Bonecal, Nasalt, Novomega, SiderAL, CardioSiderAL, DiKappa2, SiderAL Forte, and others. The company operates in Europe, the Middle East, the Far East, Asia, the United States, and Africa.

PharmaNutra SpA (MIL:PHN) Headlines

No Headlines